Leukemia Clinical Trial
Official title:
Metabolic Syndrome Following Transplant for Leukemia
RATIONALE: Gathering information about how often metabolic syndrome occurs in young
survivors of childhood leukemia who have undergone stem cell transplant may help doctors
learn more about the disease and the long-term effects of leukemia treatment. It may also
help improve the quality of life for future cancer survivors.
PURPOSE: This clinical trial is studying metabolic syndrome in adolescent and young adult
survivors of childhood leukemia who have undergone stem cell transplant.
OBJECTIVES:
- To determine the prevalence of metabolic syndrome in adolescent and young adult
survivors of childhood leukemia who have undergone hematopoietic stem cell
transplantation (HSCT) and compare the extent to which prevalence is higher in HSCT
survivors than in age- and gender-matched population norms derived from the Third
National Health and Nutrition Examination Survey (NHANES III).
- To evaluate the relationship between insulin resistance and risk factors associated
with metabolic syndrome (e.g., hypertension, obesity, hyperinsulinemia, and
dyslipidemia) as measured by euglycemic insulin clamp, fasting serum insulin, glucose,
lipids (total cholesterol, triglycerides, LDL-C, and HDL-C), blood pressure and
anthropometric measurements, and DEXA scan in these patients and compare to age- and
gender-matched population norms.
- To assess the extent to which prevalent obesity and insulin resistance are correlated
with other factors that have been identified in the causal pathway associated with the
development of metabolic syndrome and that may be altered after HSCT, including growth
hormone secretion, adipokines (adiponectin and leptin), and inflammatory mediators
(interleukin-6, tumor necrosis factor-α, and C-reactive protein).
- To evaluate the association of metabolic syndrome and early signs of impaired
endothelial function and cardiovascular changes.
- To evaluate health behaviors related to prevention of cardiovascular disease, diabetes,
and obesity, including a physical activity assessment, a dietary assessment, and a
health knowledge assessment that will be used in the analyses of metabolic syndrome,
growth hormone deficiency, and indicators of cardiovascular disease.
OUTLINE: Patients are stratified according to post-transplant follow-up period (2-9 years vs
10-15 years vs > 15 years).
Patients and their siblings undergo physical examination, a review of medical and family
history, and blood pressure and anthropometric measurements. Patients and their siblings
also undergo blood sample collection for laboratory studies (including analysis of
C-reactive protein and CBC; lipid profile and triglycerides; leptin and adipokines; free
thyroxine, TSH, IGF1, IGF3, and LH; and estradiol [females] or testosterone [males]); urine
sample collection for microalbumin determination; and other study procedures (including
euglycemic insulin clamp study; body composition and bone density [DEXA] study; bone-age
x-ray [for patients < 18 years of age]; and vascular studies). Patients also undergo growth
hormone stimulation testing.
Patients and their siblings complete questionnaires about their physical activity, dietary
habits, and health knowledge.
PROJECTED ACCRUAL: A total of 193 childhood leukemia survivors and 193 healthy siblings will
be accrued for this study.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |